Actinic keratosis (AK) is a form of skin cancer and it is also known as solar keratosis. This indication tends to affect the sun-exposed parts of the skin such as face, bald scalp, lips, and the back of the hands among others. As a result of the exposure, the skin tends to become rough, uneven and display a warty look. Approximately, 10% of the exposed areas tend to develop squamous cell carcinoma (SCC), which has the highest prevalence among rarer skin cancers. The American Academy of Dermatology has estimated that approximately 58 million people in the U.S. suffer from AK. In some rarer instances, AKs may also turn into basal cell carcinomas (BCC) – the most common form of skin cancer. Geographical location of a place is known to play a key role in development of this skin disease. Populations in countries closer to the Equator are more susceptible to be affected from AK that could eventually lead to SCC or BCC. Dermatologists, through skin tests and biopsy (if required), diagnose the disease. Both conservative treatments and invasive treatments are required for complete cure. If found early, skin cancer can be completely cured. Given large amount of ozone depletion globally, there has been rising incidence of skin cancers in both developed and developing nations. With advent in greater number of cures, the probabilities of higher diagnosis and treatments have increased manifold.
Actinic keratoses are found on areas of skin exposed to the sun – most commonly face areas such as nose & forehead, forearms, backs of hands in men, rims of ears, bald scalps, etc.
Actinic Keratosis Treatment Market: Drivers and Restraints
Some of the major proceedings for Actinic Keratosis treatment market is due to highest prevalence of actinic keratosis range from 40% to 60% in adult population, market is majorly driven by wide presence of generic drugs and is moderately competitive,. Others factors such as depletion of ozone layer, rising incidences of cancer and sedentary life style are driving the growth of the global actinic keratosis treatment market. . However, on the other hand low awareness of the actinic keratosis and welfares of its early diagnosis and lack of awareness about the available treatments for actinic keratosis are some of the factors that are restraining the global actinic keratosis treatment market.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3233
Actinic Keratosis Treatment Market: Segmentation
The global market for Actinic Keratosis Treatment Market is broadly classified because of treatment type and by end users, apart from regions.
Based on treatment type, theActinic Keratosis Treatment Market has been segmented as follows:
- By Prescription Drugs
- 5-fluorouracil (5-FU) cream
- Imiquimod cream
- Diclofenac sodium gel
- Ingenol mebutate gel
- By Invasive and Minimally Invasive Treatments
- Curettage or Scrapping
- Photodynamic therapy
- Laser Resurfacing
Based on end users, theActinic Keratosis Treatment Market has been segmented as follows:
- Private Dermatologist Office and Clinics
- Oncology Centers
- Ambulatory Surgical Centers
- Full-Service Dermatology Service Centers (Spas)
Actinic Keratosis Treatment Market: Overview
The global Actinic Keratosis Treatment Marketis expected to expand at healthy CAGR owing to rise in expenditure on research and development, growing prevalence of Actinic Keratosis, better public awareness about occurrence of Actinic Keratosis, and rise in affordability for availing treatments for AK among many others globally. Among end users, hospitals end user segment is expected to account for maximum share due to the increase treatment of Actinic Keratosisis required.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3233
Actinic Keratosis Treatment Market: Region-wise Outlook
Geographically, the global Actinic Keratosis Treatment Market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Among all the regions, North America will continue to lead the global market for Actinic Keratosis Treatment Market due to growing prevalence of Actinic Keratosis, improved public awareness about occurrence of Actinic Keratosis and associated risk of squamous cell carcinoma. Asia- Pacific is expected to account for second largest share in global market. Due to increasing cognizance in the region and speedy development in healthcare infrastructure and healthcare expenditure are the key growth factors in Asia Pacific actinic keratosis market.
Actinic Keratosis Treatment Market: Key Players
Key players operating in the global bioactive coating devices market are Valeant Pharmaceuticals, Aqua Pharmaceuticals, Inc., 3M Pharmaceuticals, Tolmar Pharmaceuticals, Inc, DUSA Pharmaceuticals, Inc. Galderma SA, Novartis, Horizon Pharma, Nuvo Research, LEO Pharma, and Fougera among others